To sum up some of the details of the article, this only applies to drugs developed using government funding. The Bayh-Dole Act of 1980 gave private companies the right to hold parents on drugs developed with public funding, but also included a safeguard, “march-in rights”, which gives the government rights to override those patents. The new order introduces a policy of exercising those rights in some cases.

It seems that if this is used the government would grant rights to a competitor to sell the drug at a lower price.

And who decides whether the price is too high or not? It’s just adding a needless middleman who is going to get his cut from the pharma lobby.